Takeda Pharmaceutical (NYSE:TAK) Rating Lowered to Hold at Zacks Research

Takeda Pharmaceutical (NYSE:TAK) was downgraded by equities research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday, Zacks reports.

Other analysts have also recently issued reports about the company. Wall Street Zen raised Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Weiss Ratings upgraded Takeda Pharmaceutical from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, September 11th. Two research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy”.

Takeda Pharmaceutical Price Performance

TAK stock opened at $17.87 on Thursday. The company has a current ratio of 1.14, a quick ratio of 0.62 and a debt-to-equity ratio of 0.58. The company has a market capitalization of $57.25 billion, a P/E ratio of 52.55 and a beta of -0.07. The business has a 50 day simple moving average of $18.06 and a 200-day simple moving average of $17.24. Takeda Pharmaceutical has a twelve month low of $12.99 and a twelve month high of $19.10.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Thursday, July 30th. The company reported $0.95 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.54. The firm had revenue of $7.50 billion for the quarter, compared to analysts’ expectations of $7.13 billion. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%.Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. As a group, equities analysts anticipate that Takeda Pharmaceutical will post 1.56 EPS for the current year.

Insider Buying and Selling

In other news, insider Giles Platford sold 31,083 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $17.10, for a total transaction of $531,519.30. Following the sale, the insider owned 315,838 shares in the company, valued at $5,400,829.80. This trade represents a 8.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Julie Kim sold 89,090 shares of Takeda Pharmaceutical stock in a transaction on Monday, August 10th. The shares were sold at an average price of $17.10, for a total value of $1,523,439.00. Following the completion of the sale, the chief executive officer directly owned 391,489 shares of the company’s stock, valued at approximately $6,694,461.90. This represents a 18.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 627,457 shares of company stock worth $10,981,175 in the last 90 days. 0.04% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Takeda Pharmaceutical

Large investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC grew its holdings in Takeda Pharmaceutical by 14.2% in the 1st quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company’s stock valued at $55,358,000 after buying an additional 370,800 shares during the period. Quantinno Capital Management LP lifted its holdings in shares of Takeda Pharmaceutical by 20.6% during the 1st quarter. Quantinno Capital Management LP now owns 1,289,326 shares of the company’s stock worth $23,878,000 after acquiring an additional 219,999 shares during the period. Bleakley Financial Group LLC lifted its holdings in shares of Takeda Pharmaceutical by 19.0% during the 1st quarter. Bleakley Financial Group LLC now owns 431,602 shares of the company’s stock worth $7,993,000 after acquiring an additional 68,844 shares during the period. Royal Bank of Canada boosted its position in shares of Takeda Pharmaceutical by 11.0% in the first quarter. Royal Bank of Canada now owns 614,851 shares of the company’s stock worth $11,386,000 after acquiring an additional 60,725 shares during the last quarter. Finally, Engineers Gate Manager LP acquired a new stake in shares of Takeda Pharmaceutical in the second quarter worth approximately $712,000. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited is a global biopharmaceutical company headquartered in Tokyo, Japan. The company researches, develops, manufactures and commercializes prescription medicines and vaccines, with a focus on gastrointestinal and inflammatory diseases, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines.

Takeda’s portfolio includes treatments such as Entyvio for inflammatory bowel disease, Takhzyro for hereditary angioedema, Iclusig and Ninlaro for certain blood cancers, and Trintellix for major depressive disorder.